Investors in BioNTech SE are preparing for a key financial update, with the company confirming it will release its fourth-quarter and full-year 2025 results on March 10, 2026. This disclosure will serve as a critical benchmark for assessing the progress of the biotech firm’s strategic realignment toward oncology, a transition that is now central to its future.
Financial Context and Strategic Shift
The accompanying conference call is scheduled for 2:00 p.m. Central European Time. As of the end of 2025, BioNTech reported holding cash, cash equivalents, and investments totaling €17.2 billion. Its revenue guidance for the full year 2025 was set between €2.6 billion and €2.8 billion, with the company noting that it does not anticipate product revenue from its oncology portfolio until 2026.
This financial snapshot arrives at a pivotal moment. BioNTech is aggressively shifting its focus away from declining COVID-19 vaccine revenue from Comirnaty and accelerating its cancer research initiatives. For the current year, the Mainz-based company has announced plans for seven data readouts from late-stage trials and the initiation of six additional Phase 3 studies. By the end of 2026, it aims to have 15 Phase 3 trials actively underway.
A Broad Oncology Pipeline in Focus
The company’s clinical pipeline features several advanced candidates attracting significant attention. Gotistobart, an immunomodulator, is in Phase 3 development for squamous non-small cell lung cancer and received FDA Orphan Drug designation in January. Another promising asset, trastuzumab pamirtecan—an antibody-drug conjugate—is being evaluated for HER2-low breast cancer and endometrial carcinoma. Furthermore, the mRNA cancer vaccine candidate BNT113, targeting HPV16-positive head and neck cancers, was granted FDA Fast Track status also in January.
Should investors sell immediately? Or is it worth buying BioNTech?
Additional programs underscore the diversity of the pipeline. These include autogene cevumeran for colorectal cancer and pumitamig, developed in collaboration with Bristol Myers Squibb, which is in Phase 3 for triple-negative breast cancer in China. This wide spread across various tumor types highlights BioNTech’s ambition to establish itself as a diversified oncology company.
Key Investor Considerations for the March Update
When the figures are released, market participants will be scrutinizing several specific areas. The ongoing trajectory of Comirnaty revenue remains a focal point. BioNTech has forecast a further decline in COVID-19 vaccine sales for the current year, citing updated vaccination recommendations and reduced demand. Concurrently, research and development expenses are climbing, with cost control becoming a crucial factor as the company manages over 25 ongoing Phase 2 and Phase 3 clinical trials.
Another completed strategic move will be in view: the acquisition of CureVac, finalized in December 2025, through which approximately 86.75% of CureVac shares were tendered. The integration process is intended to bolster BioNTech’s overall mRNA technology platform. An updated financial outlook for 2026 is also likely to be a feature of the upcoming announcement.
Ad
BioNTech Stock: Buy or Sell?! New BioNTech Analysis from February 27 delivers the answer:
The latest BioNTech figures speak for themselves: Urgent action needed for BioNTech investors. Is it worth buying or should you sell? Find out what to do now in the current free analysis from February 27.
BioNTech: Buy or sell? Read more here...
